Drug Repurposing Market to Reach USD 43.21 Bn by 2031 as AI-Driven Drug Discovery Advances | Mordor Intelligence

Drug repurposing market to register a CAGR of 2.90% during 2026–2031, with North America leading the global market.

HYDERABAD, TELANGANA, INDIA, November 4, 2026 /EINPresswire.com/ -- According to Mordor Intelligence, the drug repurposing market size is estimated at USD 37.46 billion in 2026 and is projected to reach USD 43.21 billion by 2031, expanding at a CAGR of 2.90% during the forecast period (2026–2031). The market is benefiting from pharmaceutical companies' efforts to identify new therapeutic applications for existing drugs, reduce research and development costs, and shorten development timelines. Advances in artificial intelligence, high-throughput in-silico screening, real-world evidence analysis, and molecular profiling are further supporting drug repositioning research. Growing interest in rare and orphan diseases, combined with regulatory pathways that allow developers to leverage previously established safety and clinical data, is also creating opportunities across pharmaceutical companies, biotechnology firms, academic institutions, and contract research organizations.

Drug Repurposing Market Key Growth Factors

AI-Enabled Screening Accelerates Drug Repurposing Research

Artificial intelligence and computational screening are expanding the ability of researchers to identify potential new uses for existing drug compounds. Machine learning, deep learning, and biomedical knowledge graphs can analyze relationships between drugs, molecular targets, disease pathways, and patient data to prioritize candidates for further investigation. These approaches can help researchers screen large compound libraries and identify potential therapeutic applications more efficiently than relying exclusively on conventional laboratory screening. As pharmaceutical companies and biotechnology firms increase investment in computational drug discovery, AI-enabled platforms are becoming an important part of drug repurposing research.

Regulatory Pathways and Existing Safety Data Support Drug Development

Drug repurposing can offer development advantages because previously investigated or approved compounds may have established pharmacokinetic, safety, and manufacturing information. In the United States, the FDA's 505(b)(2) regulatory pathway allows developers to rely partly on existing findings when submitting applications for certain new drug uses or formulations. This can reduce the need to repeat some development activities, depending on the drug and proposed indication. Greater use of existing clinical evidence and real-world data is also supporting interest in repositioning established medicines for additional therapeutic applications.

Growing Focus on Rare Diseases Expands Repurposing Opportunities

The limited availability of approved treatments for many rare and orphan diseases is encouraging researchers to investigate existing medicines for new indications. Drug repurposing can provide an alternative development strategy by drawing on compounds with previously established safety information and biological evidence. Orphan-drug incentives, patient registries, academic research partnerships, and specialized clinical trial programs are supporting activity in this area. According to Mordor Intelligence, rare and orphan diseases are projected to be the fastest-growing therapeutic area in the market, registering a CAGR of 14.8% through 2031.

“As pharmaceutical research increasingly explores new applications for established medicines, decision-makers benefit from market intelligence grounded in transparent sourcing, consistent validation, and balanced market assessment. Mordor Intelligence provides a structured view of competitive activity, research priorities, and factors influencing future demand,” says Soumya Goud, Senior Research Manager, Mordor Intelligence.

Drug Repurposing Market Recent Industry Developments

May 2026 – Researchers published a review examining the role of artificial intelligence in pharmaceutical research and drug repurposing. Published in Briefings in Bioinformatics, the study reviewed machine learning, deep learning, biological network analysis, and other AI methods used to identify new therapeutic applications for existing drugs. It also discussed data availability, model interpretability, and validation challenges.

June 2026 – Researchers introduced a diffusion model-based approach to AI-driven drug repositioning. Published in the Journal of Computational Science, the study used biomedical knowledge graphs and graph-based learning to improve predictions of potential drug-disease relationships, highlighting the role of computational methods in identifying new therapeutic applications.

Drug Repurposing Market Segmentation Insights

By Therapeutic Area

Oncology

CNS Disorders

Cardiovascular Diseases

Infectious Diseases

Metabolic Disorders

By Drug Molecule Type

Small-Molecule Drugs

Biologics and Peptides

By Development Stage

Pre-clinical

Phase I

Phase II

Phase III

Approved / Marketed

By Route of Administration

Oral

Injectable

Topical / Others

By End User

Pharmaceutical and Biotechnology Companies

Academic and Research Institutes

Contract Research Organizations (CROs)

By Geography

North America

United States

Canada

Mexico

Europe

Germany

United Kingdom

France

Italy

Spain

Rest of Europe

Asia-Pacific

China

Japan

India

South Korea

Australia

Rest of Asia-Pacific

Middle East and Africa

GCC

South Africa

Rest of Middle East and Africa

South America

Brazil

Argentina

Rest of South America

Drug Repurposing Market Regional Insights

North America represents the largest regional market, accounting for 45.3% of global revenue in 2025. The region benefits from established pharmaceutical and biotechnology industries, strong research infrastructure, and regulatory pathways that support the development of new indications for existing medicines. Investment in AI-enabled drug discovery, clinical research, and real-world evidence platforms is further supporting its position in the market.

Europe represents an established drug repurposing market, supported by pharmaceutical research capabilities, academic collaborations, and regulatory coordination across the region. Research institutions and biotechnology companies are exploring computational screening, molecular profiling, and clinical evidence to identify additional uses for existing medicines. Continued interest in rare-disease treatment development is also supporting research activity.

Asia-Pacific is projected to be the fastest-growing regional market, registering a CAGR of 11.6% during 2026–2031. Growth is supported by expanding clinical trial infrastructure, increasing pharmaceutical research investment, and rising adoption of computational drug discovery technologies. China, India, Japan, and South Korea are contributing to regional research activity through investments in biotechnology, clinical development, and healthcare innovation.

The Drug Repurposing Market report is also available in the following languages:

Japanese: https://www.mordorintelligence.com/ja/industry-reports/drug-repurposing-market?utm_source=einpr

French: https://www.mordorintelligence.com/fr/industry-reports/drug-repurposing-market?utm_source=einpr

German: https://www.mordorintelligence.com/de/industry-reports/drug-repurposing-market?utm_source=einpr

Spanish: https://www.mordorintelligence.com/es/industry-reports/drug-repurposing-market?utm_source=einpr

Portuguese: https://www.mordorintelligence.com/pt/industry-reports/drug-repurposing-market?utm_source=einpr

Drug Repurposing Market Competitive Landscape

The drug repurposing market is moderately fragmented, with established pharmaceutical companies, biotechnology firms, and AI-focused drug discovery companies competing across therapeutic areas and development stages. Recursion Pharmaceuticals, BenevolentAI, Novartis, Pfizer, Roche, and other major participants are involved in identifying new therapeutic applications for existing drug candidates. Competition is increasingly influenced by computational screening capabilities, proprietary compound libraries, clinical evidence, research partnerships, and the ability to advance promising candidates through development and regulatory pathways. Collaboration between pharmaceutical companies, technology providers, academic institutions, and CROs is also shaping the competitive environment.

Drug Repurposing Market Key Companies

Recursion Pharmaceuticals

BenevolentAI

Novartis AG

Pfizer Inc.

Roche Holding AG

GSK plc

Eli Lilly and Company

Merck & Co., Inc.

Sanofi

AstraZeneca plc

Takeda Pharmaceutical

Bayer AG

Insilico Medicine

Exscientia plc

Healx

Atomwise

Biovista

CelerisTx

Gilead Sciences

Johnson & Johnson

Discover the latest trends, growth opportunities, and competitive developments in the Drug Repurposing Market: https://www.mordorintelligence.com/industry-reports/drug-repurposing-market?utm_source=einpr

Explore More Industry Research Reports by Mordor Intelligence:

Medical Device Connectivity Market Size

The Medical Device Connectivity Market is expected to grow from USD 5.91 billion in 2027 to USD 16.61 billion by 2032, registering a CAGR of 22.95%, supported by increasing adoption of connected healthcare technologies, rising demand for real-time patient data, and growing integration of medical devices with hospital information systems.

Meningococcal Vaccines Market Share

The Meningococcal Vaccines Market is projected to expand from USD 3.34 billion in 2026 to USD 4.71 billion by 2031, at a CAGR of 7.12%, driven by increasing immunization efforts, greater awareness of meningococcal disease prevention, and continued demand for effective vaccination programs.

https://www.mordorintelligence.com/industry-reports/meningococcal-vaccines-market?utm_source=einpr

Amniotic Membrane Market Trends

The Amniotic Membrane Market is expected to grow from USD 3.75 billion in 2026 to USD 6.58 billion by 2031, registering a CAGR of 11.92%, supported by expanding applications in wound care, ophthalmology, and surgical procedures, along with growing demand for regenerative and tissue-based therapies.

https://www.mordorintelligence.com/industry-reports/amniotic-membrane-market?utm_source=einpr

High Content Screening Market Analysis

The High Content Screening Market is projected to increase from USD 2.14 billion in 2026 to USD 2.84 billion by 2031, at a CAGR of 5.83%, driven by rising demand for advanced drug discovery tools, increasing use of cell-based assays, and growing adoption of automated imaging and analysis technologies.

https://www.mordorintelligence.com/industry-reports/high-content-screening-hts-market?utm_source=einpr

Induced Pluripotent Stem Cells Market

The Induced Pluripotent Stem Cells Market is expected to expand from USD 2.59 billion in 2026 to USD 4.14 billion by 2031, registering a CAGR of 9.83%, supported by growing investment in regenerative medicine, increasing applications in disease modeling and drug discovery, and continued advances in stem cell research.

https://www.mordorintelligence.com/industry-reports/induced-pluripotent-stem-cells-market?utm_source=einpr

About Mordor Intelligence

Mordor Intelligence is a global market intelligence firm, founded in 2014, helping businesses make informed decisions through data-driven insights, industry expertise, and advanced analytics. With 550+ domain experts and on-ground specialists across 150+ countries, the company delivers comprehensive intelligence across aerospace & defense, agriculture, automation, automotive, chemicals & materials, consumer goods & services, electronics, energy & power, financial services, food & beverages, healthcare, hospitality & tourism, information & communications technology, and logistics. Its offerings include syndicated industry reports, custom research and advisory, and subscription platforms such as Synapse. Mordor Intelligence is ISO 9001:2015 and ISO/IEC 27001:2022 certified, a member of ESOMAR and the Market Research Society of India, and a four-time Great Place to Work^® honoree.

For media inquiries or further information, please contact: 
media@mordorintelligence.com 
Mordor Intelligence Private Limited 
https://www.mordorintelligence.com/

Jignesh Thakkar
Mordor Intelligence Private Limited 
+ +1 617-765-2493
Visit us on social media:
LinkedIn
Instagram
Facebook
X
Other